HomeCompareSZUKF vs ARCC

SZUKF vs ARCC: Dividend Comparison 2026

SZUKF yields 2.21% · ARCC yields 10.65%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 SZUKF wins by $8.8K in total portfolio value· pulled ahead in Year 5
10 years
SZUKF
SZUKF
● Live price
2.21%
Share price
$30.30
Annual div
$0.67
5Y div CAGR
24%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$33.3K
Annual income
$2,934.36
Full SZUKF calculator →
ARCC
Ares Capital Corporation
● Live price
10.65%
Share price
$18.02
Annual div
$1.92
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$24.5K
Annual income
$1.14
Full ARCC calculator →

Portfolio growth — SZUKF vs ARCC

📍 SZUKF pulled ahead of the other in Year 5

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSZUKFARCC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SZUKF + ARCC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SZUKF pays
ARCC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SZUKF
Annual income on $10K today (after 15% tax)
$187.93/yr
After 10yr DRIP, annual income (after tax)
$2,494.21/yr
ARCC
Annual income on $10K today (after 15% tax)
$905.66/yr
After 10yr DRIP, annual income (after tax)
$0.97/yr
At 15% tax rate, SZUKF beats the other by $2,493.24/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SZUKF + ARCC for your $10,000?

SZUKF: 50%ARCC: 50%
100% ARCC50/50100% SZUKF
Portfolio after 10yr
$28.9K
Annual income
$1,467.75/yr
Blended yield
5.08%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ARCC right now

SZUKF
No analyst data
Altman Z
2.7
Piotroski
4/9
ARCC
Analyst Ratings
24
Buy
7
Hold
Consensus: Buy
Price Target
$21.88
+21.4% upside vs current
Range: $21.00 — $23.00
Altman Z
0.8
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SZUKF buys
0
ARCC buys
13
PoliticianChamberTickerTypeAmountDate
John Fetterman🏛 Senate$ARCC▲ Buy$1,001 - $15,0002025-09-09
John Fetterman🏛 Senate$ARCC▼ Sell$1,001 - $15,0002025-09-04
Ashley Moody🏛 Senate$ARCC▲ Buy$15,001 - $50,0002025-04-04
John Fetterman🏛 Senate$ARCC▲ Buy$1,001 - $15,0002025-02-18
Dave McCormick🏛 Senate$ARCC▲ Buy$250,001 - $500,0002025-01-17
Pete Sessions🏢 House$ARCC▼ Sell$1,001 - $15,0002023-11-01
Pete Sessions🏢 House$ARCC▲ Buy$569.252023-10-06
Pete Sessions🏢 House$ARCC▲ Buy$0 - $1,0002023-10-06
Pete Sessions🏢 House$ARCC▲ Buy$155.922023-08-15
Pete Sessions🏢 House$ARCC▲ Buy$0 - $1,0002023-08-15
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSZUKFARCC
Forward yield2.21%10.65%
Annual dividend / share$0.67$1.92
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR24%-50%
Portfolio after 10y$33.3K$24.5K
Annual income after 10y$2,934.36$1.14
Total dividends collected$11.3K$1.1K
Payment frequencyquarterlyquarterly
SectorStockBDC

Year-by-year: SZUKF vs ARCC ($10,000, DRIP)

YearSZUKF PortfolioSZUKF Income/yrARCC PortfolioARCC Income/yrGap
1$10,974$274.15$11,373$532.74$399.00ARCC
2$12,091$348.66$12,608$279.46$517.00ARCC
3$13,383$445.17$13,809$142.90$426.00ARCC
4$14,890$571.01$15,042$72.20$152.00ARCC
5← crossover$16,669$736.28$16,341$36.27+$328.00SZUKF
6$18,791$955.18$17,732$18.18+$1.1KSZUKF
7$21,354$1,247.86$19,231$9.10+$2.1KSZUKF
8$24,492$1,643.38$20,851$4.55+$3.6KSZUKF
9$28,391$2,184.35$22,605$2.28+$5.8KSZUKF
10$33,313$2,934.36$24,504$1.14+$8.8KSZUKF

SZUKF vs ARCC: Complete Analysis 2026

SZUKFStock

Suzuken Co., Ltd., together with its subsidiaries, primarily engages in the wholesale of pharmaceuticals in Japan and internationally. The company operates in four segments: Pharmaceutical Distribution Business, Pharmaceutical Manufacturing Business, Pharmacy Business, and Healthcare-Related Services Business. The Pharmaceutical Distribution Business segment procures ethical drugs, diagnostic reagents, medical equipment and supplies, and other health-related items from manufacturers and supplies to medical institutions and pharmacies. The Pharmaceutical Manufacturing Business segment engages in the research and development, manufacturing, and marketing of ethical pharmaceuticals and diagnostic products focusing on the areas of diabetes and kidney diseases. The Pharmacy Business segment provides services through family pharmacists, as well as improves the operations of local pharmacies and provides educational support. The Healthcare-Related Services Business segment provides manufacturer support services, such as contract distribution for manufacturers; distribution of orphan drugs; and nursing care services, as well as develops, manufactures, and sells electrocardiographs, sphygmomanometers, stethoscopes, medical materials, and health promotion equipment. Suzuken Co., Ltd. also publishes medical magazines for medical institutions. The company has collaboration with Bushu Pharmaceuticals Ltd. provide contract specialty drug services. Suzuken Co., Ltd. was founded in 1932 and is headquartered in Nagoya, Japan.

Full SZUKF Calculator →

ARCCBDC

Ares Capital Corporation is a business development company specializing in acquisition, recapitalization, mezzanine debt, restructurings, rescue financing, and leveraged buyout transactions of middle market companies. It also makes growth capital and general refinancing. It prefers to make investments in companies engaged in the basic and growth manufacturing, business services, consumer products, health care products and services, and information technology service sectors. The fund will also consider investments in industries such as restaurants, retail, oil and gas, and technology sectors. It focuses on investments in Northeast, Mid-Atlantic, Southeast and Southwest regions from its New York office, the Midwest region, from the Chicago office, and the Western region from the Los Angeles office. The fund typically invests between $20 million and $200 million and a maximum of $400 million in companies with an EBITDA between $10 million and $250 million. It makes debt investments between $10 million and $100 million The fund invests through revolvers, first lien loans, warrants, unitranche structures, second lien loans, mezzanine debt, private high yield, junior capital, subordinated debt, and non-control preferred and common equity. The fund also selectively considers third-party-led senior and subordinated debt financings and opportunistically considers the purchase of stressed and discounted debt positions. The fund prefers to be an agent and/or lead the transactions in which it invests. The fund also seeks board representation in its portfolio companies.

Full ARCC Calculator →
📬

Get this SZUKF vs ARCC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SZUKF vs SCHDSZUKF vs JEPISZUKF vs OSZUKF vs KOSZUKF vs MAINSZUKF vs HTGCSZUKF vs GBDCSZUKF vs ORCC

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.